Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03691064 · ClinicalTrials.gov registry record
Post-Authorization Long-Term Safety Study of LUTATHERA
A clinical trial of Neuroendocrine Tumors, sponsored by Advanced Accelerator Applications.
- Active
- Registry status
- 1,014
- Enrollment target
- 20
- Study locations
NCT03691064: Active study of Neuroendocrine Tumors, sponsored by Advanced Accelerator Applications.
NCT03691064 is a study of Neuroendocrine Tumors that is active but no longer recruiting, run by Advanced Accelerator Applications. The registered enrollment target is 1,014 participants, above the 160-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (534% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03691064, a study of Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Advanced Accelerator Applications.
- ACTIVE NOT RECRUITING
- Registry status
- 1,014 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
Primary Outcome
incidence of secondary cancers
Conditions Studied
Interventions
- DRUG LUTATHERA
Study Locations (20)
Other
- Novartis Investigative site - Clichy
- Novartis Investigative site - Lyon
- Novartis Investigative site - Villejuif
- Novartis Investigative site - Birmingham
- Novartis Investigative site - Cambridge
- Novartis Investigative site - Glasgow
- Novartis Investigative site - Liverpool
- Novartis Investigative site - London
- Novartis Investigative site - London
- Novartis Investigative site - London
- Novartis Investigative site - London
- Novartis Investigative site - Manchester
- Novartis Investigative site - Sheffield
Arizona
- Banner MD Anderson Cancer Center - Phoenix
Ohio
- The Ohio State University Wexner Medical Center - Portland
Oregon
- Oregon Health & Sciences University Hospital - Portland
Washington
- Virginia Mason in Seattle - Seattle
Coimbra District
- Novartis Investigative site - Coimbra
La Corunya
- Novartis Investigative site - Santiago de Compostela
Madrid
- Novartis Investigative site - Majadahonda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,014 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2027-09-30 |
What the registry record for NCT03691064 still lists
NCT03691064 is an observational study that tracks outcomes without assigning an intervention. Its 1,014 participants enrollment target places it among the larger protocols in the corpus, above the 160-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (534% higher).
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which LUTATHERA is the first listed.
NCT03691064 names 20 study sites across 8 states, led by Other, Arizona, Ohio.
Frequently Asked Questions
What is clinical trial NCT03691064 about?
NCT03691064 is a clinical study titled "Post-Authorization Long-Term Safety Study of LUTATHERA". Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
What is the current status of trial NCT03691064?
This trial is currently active not recruiting. The enrollment target is 1,014 participants. The study started on 2018-11-28. Estimated completion is 2027-09-30.
What conditions does trial NCT03691064 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT03691064?
The interventions under investigation include: LUTATHERA (DRUG).
Who is sponsoring clinical trial NCT03691064?
This trial is sponsored by Advanced Accelerator Applications, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03691064 being conducted?
This trial has 20 study locations across Arizona, Ohio, Oregon, Washington, Coimbra District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03691064's enrollment target sits among peer trials
1,014 2nd of 52 the highest of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI